• Email
  • Help

Withdrawal statement

On 17 January 2007 Pfizer Ltd officially notified the Committee for Medicinal Products for Veterinary Use (CVMP) that it wishes to withdraw its application for a new indication for the treatment of bovine interdigital necrobacillosis associated with Bacteroides melaninogenicus, Bacteroides nodosus and Fusobacterium necrophorum.

Key facts

Product details for Draxxin
INN or common name


Active substancetulathromycin
Date of withdrawal17/01/2007
Company making the application

Zoetis Belgium SA

Withdrawal typePost-authorisation

All documents

Name Language First published Last updated
Withdrawal letter : Draxxin (English only) 2007-01-17  


Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CVMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CVMP's evaluation is completed ('day 120').